Aurora kinase inhibitors
Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.
1. A compound, or a pharmaceutically acceptable salt thereof, having the formula:
wherein
R 1 is a substituted or unsubstituted C 5 cycloalkyl, substituted or unsubstituted 5 to 6 membered heteroaryl;
R 2 is hydrogen, halogen, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCH 3 , —OCF 3 , —OCHF 2 , —C(O)CH 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R 3 is independently halogen, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCH 3 , —OCF 3 , —OCHF 2 , —C(O)CH 3 , unsubstituted alkyl, or unsubstituted heteroalkyl; and
n is independently an integer from 0 to 5.
2. The compound of claim 1 , wherein R 1 is an unsubstituted cyclopentyl or unsubstituted furanyl.
3. The compound of claim 1 , wherein R 2 is hydrogen, halogen, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCH 3 , —OCF 3 , —OCHF 2 , —C(O)CH 3 , substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C 6 -C 10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl.
4. The compound of claim 1 , wherein R 2 is hydrogen or unsubstituted C 1 -C 4 alkyl.
5. The compound of claim 1 , wherein R 3 is independently halogen, —CF 3 , —CCl 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —NHC(O)NH 2 , —NHSO 2 H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCH 3 , —OCF 3 , —OCHF 2 , —C(O)CH 3 , unsubstituted C 1 -C 4 alkyl, or unsubstituted 2 to 4 membered heteroalkyl.
6. The compound of claim 1 , wherein the compound has the formula:
7. The compound of claim 1 , wherein the compound has the formula:
8. A pharmaceutical composition, comprising a pharmaceutically acceptable excipient and a compound, or a pharmaceutically acceptable salt thereof, of claim 1 .
9. The compound of claim 1 , wherein R 1 is a substituted or unsubstituted C 5 cycloalkyl.
10. The compound of claim 9 , wherein R 1 is unsubstituted cyclopentyl.